143 related articles for article (PubMed ID: 22881584)
21. Basal Cell Carcinoma Multiplicity - a Retrospective Analysis of 899 Biopsy-proven Patients from a Single Institute.
Bartos V; Kullová M
Klin Onkol; 2017; 30(3):197-201. PubMed ID: 28612616
[TBL] [Abstract][Full Text] [Related]
22. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
Tillman DK; Carroll MT
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s7-14. PubMed ID: 18277457
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic analysis of trichoblastoma and comparison with nodular basal cell carcinoma.
Bourlond F; Battistella M; Amici JM; Dousset L; Vergier B; Beylot-Barry M; Cribier B
Ann Dermatol Venereol; 2021 Sep; 148(3):177-182. PubMed ID: 34176642
[TBL] [Abstract][Full Text] [Related]
24. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma.
Graells J; Ojeda RM; García-Cruz A
Actas Dermosifiliogr; 2014; 105(1):53-9. PubMed ID: 24139468
[TBL] [Abstract][Full Text] [Related]
25. Clinical factors predictive for histological aggressiveness of basal cell carcinoma: A prospective study of 2274 cases.
Amici JM; Dousset L; Battistella M; Vergier B; Bailly JY; Cogrel O; Gusdorf L; Alfaro C; Ezzedine K; Cribier B; Beylot-Barry M
Ann Dermatol Venereol; 2021 Mar; 148(1):23-27. PubMed ID: 31831218
[TBL] [Abstract][Full Text] [Related]
26. Excising basal cell carcinoma in general practice.
Bostock-Ling N
Aust Fam Physician; 2006 Jul; 35(7):558-60. PubMed ID: 16820836
[TBL] [Abstract][Full Text] [Related]
27. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.
Berman B; Sullivan T; De Araujo T; Nadji M
Br J Dermatol; 2003 Nov; 149 Suppl 66():59-61. PubMed ID: 14616354
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas.
Boaventura P; Pereira D; Mendes A; Batista R; da Silva AF; Guimarães I; Honavar M; Teixeira-Gomes J; Lopes JM; Máximo V; Soares P
J Dermatol Sci; 2014 Jan; 73(1):31-9. PubMed ID: 24091058
[TBL] [Abstract][Full Text] [Related]
29. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype.
Scrivener Y; Grosshans E; Cribier B
Br J Dermatol; 2002 Jul; 147(1):41-7. PubMed ID: 12100183
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis.
Vidal D; Matías-Guiu X; Alomar A
Br J Dermatol; 2004 Sep; 151(3):656-62. PubMed ID: 15377354
[TBL] [Abstract][Full Text] [Related]
31. Basal cell carcinoma in a series of renal transplant recipients: epidemiology and clinicopathologic features.
Mertz KD; Proske D; Kettelhack N; Kegel C; Keusch G; Schwarz A; Ambühl PM; Pfaltz M; Kempf W
Int J Dermatol; 2010 Apr; 49(4):385-9. PubMed ID: 20465691
[TBL] [Abstract][Full Text] [Related]
32. Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients.
Kricker A; Armstrong B; Hansen V; Watson A; Singh-Khaira G; Lecathelinais C; Goumas C; Girgis A
J Am Acad Dermatol; 2014 Mar; 70(3):456-64. PubMed ID: 24373780
[TBL] [Abstract][Full Text] [Related]
33. Interventions for basal cell carcinoma of the skin.
Bath-Hextall FJ; Perkins W; Bong J; Williams HC
Cochrane Database Syst Rev; 2007 Jan; (1):CD003412. PubMed ID: 17253489
[TBL] [Abstract][Full Text] [Related]
34. Interventions for basal cell carcinoma of the skin.
Bath FJ; Bong J; Perkins W; Williams HC
Cochrane Database Syst Rev; 2003; (2):CD003412. PubMed ID: 12804465
[TBL] [Abstract][Full Text] [Related]
35. Hyperspectral imaging system in the delineation of Ill-defined basal cell carcinomas: a pilot study.
Salmivuori M; Neittaanmäki N; Pölönen I; Jeskanen L; Snellman E; Grönroos M
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):71-78. PubMed ID: 29846972
[TBL] [Abstract][Full Text] [Related]
36. Increased Marginal Stiffness Differentiates Infiltrative From Noninfiltrative Cutaneous Basal Cell Carcinomas in the Facial Area: A Prospective Study.
Alfageme F; Salgüero I; Nájera L; Suarez ML; Roustan G
J Ultrasound Med; 2019 Jul; 38(7):1841-1845. PubMed ID: 30467885
[TBL] [Abstract][Full Text] [Related]
37. Occurrence of metachronous basal cell carcinomas: a prognostic model.
Smedinga H; Verkouteren JAC; Steyerberg EW; Hofman A; Nijsten T; Vergouwe Y
Br J Dermatol; 2017 Oct; 177(4):1113-1121. PubMed ID: 28664573
[TBL] [Abstract][Full Text] [Related]
38. Frequency of facial basal cell carcinoma does not correlate with site-specific UV exposure.
Heckmann M; Zogelmeier F; Konz B
Arch Dermatol; 2002 Nov; 138(11):1494-7. PubMed ID: 12437456
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of incompletely excised basal cell carcinomas of the skin.
Rippey JJ; Rippey E
Med J Aust; 1997 Jun; 166(11):581-3. PubMed ID: 9201177
[TBL] [Abstract][Full Text] [Related]
40. Are there sufficient numbers of low-risk basal cell carcinomas to justify general practitioners (family physicians) carrying out basal cell carcinoma surgery?
Fremlin GA; Gomez P; Halpern J
Clin Exp Dermatol; 2016 Mar; 41(2):138-41. PubMed ID: 26189609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
